Trial reportBJOG : an international journal of obstetrics and gynaecology2026
Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised Trial.
Trial report in BJOG : an international journal of obstetrics and gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
objectiveTo compare the trajectories of placental biomarkers throughout pregnancy after aspirin discontinuation at 24-28 weeks with those of a cohort treated until 36 weeks of gestation.
designA longitudinal secondary analysis of the StopPRE trial, using repeated measures of soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and their ratio.
settingNine maternity hospitals across Spain. POPULATION: The original StopPRE trial included 936 women at high risk for preterm preeclampsia based on first-trimester screening. All participants received aspirin 150 mg daily until randomisation at 24-28 weeks. At that point, 463 women were assigned to continue aspirin until 36 weeks, while 473 were assigned to discontinue it.
methodssFlt-1, PlGF, sFlt-1/PlGF were measured at baseline (24-28 weeks) and during follow-up visits at 28-32, 32-36, and after 36 weeks of gestation. Linear mixed-effects models (LMM) with treatment-by-gestational age interaction were used to analyze biomarker trajectories over time.
main outcome measuresDifferences in trajectories of raw values and multiples of the median for sFlt-1, PlGF, sFlt-1/PlGF between groups.
resultsAmong 463 participants in the aspirin continuation group and 473 in the discontinuation group, 3483 measurements of each biomarker were analysed. There were no significant differences in the trajectories of sFlt-1, PlGF, or sFlt-1/PlGF between groups (p-values for raw analysis: 0.662, 0.728 and 0.979, respectively).
conclusionsIn women at high risk of preterm preeclampsia, discontinuing aspirin at 24-28 weeks did not alter the trajectories of placental biomarkers. This may explain why stopping aspirin did not increase preterm PE risk in the StopPRE trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.